Derivation Web

source_f4d74ff34b3b4d86

by researka:v2 · 2026-05-27 14:12:46.023458+04:00

# Alpha memo — acarbose

**Headline:** Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy
**Alpha score:** 100/100
**Alpha triage:** `high` (internal ranking; not a certainty claim)
**Confidence:** `evidence_backed_signal`
**Memo surface:** `unclassified`
**Snapshot:** `2026-05-27T09-58-52Z`
**Run:** `acarbose-evidence-2026-05-27T09-58-52Z`
**Direct source breadth:** `1` direct cited source(s)
**Source breadth:** `5/5` unique cited source(s)

## One-sentence thesis

The direct receipts support a narrow working claim: reduced risk associated with acarbose was only observed... in non-users of metformin (adjusted hazard ratio, 0.635; 95% confidence interval, 0.481-0.837); users of all three drugs had the lowest risk of dementia (hazard ratio, 0.406; 95% confidence interval, 0.178-0.925). The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.

## Why this is surprising

Real tension: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.

## Evidence receipts

- `fact_id=187300` (`A_core`) — reduced risk associated with acarbose was only observed... in non-users of metformin (adjusted hazard ratio, 0.635; 95% confidence interval, 0.481-0.837) DOI `10.14336/ad.2019.0621`
- `fact_id=187299` (`A_core`) — users of all three drugs had the lowest risk of dementia (hazard ratio, 0.406; 95% confidence interval, 0.178-0.925) DOI `10.14336/ad.2019.0621`
- `fact_id=187298` (`A_core`) — 0.918 (0.845-0.998) for every 1-year increment of cumulative duration of acarbose therapy DOI `10.14336/ad.2019.0621`

## Context receipts

- `fact_id=135514` (`A_core`) — The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose and voglibose groups. DOI `10.3346/jkms.2014.29.1.90`
- `fact_id=70369` (`A_core`) — Acarbose increased male median lifespan by 22% (P < 0.0001) DOI `10.1111/acel.12170`
- `fact_id=135510` (`A_core`) — acarbose produced 51% decrease in maltose loaded diabetic rats DOI `10.4236/jdm.2012.21013`
- `fact_id=108410` (`A_core`) — significantly increased (3%) in females only at 1,000 ppm DOI `10.1111/acel.12898`

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and next extraction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- The core claim rests on 1 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- _Counter-evidence not classified yet._

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.
- Run a follow-up pass that either connects each context receipt to the lead claim or splits it into a separate memo.

## Provenance / priority

- **Topic:** `acarbose`
- **Author:** Dom Lynch
- **ORCID:** _not configured_
- **Version:** 1.0
- **License:** CC BY-NC 4.0
- **Canonical URL:** _not assigned_
- **Suggested citation:** Dom Lynch. (2026). Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy. ReseaRka Evidence Index. Version 1.0.
- **Run bundle SHA-256:** `3d52b42b2eef9077a0c62041abf8adb8d43ceebe45f152cf94dee9baec1ad512`
- **Memo SHA-256:** `126e56cdc4e7c1539113e09c095c76b911dc397c6e84a0370737595eb5612c63`
- **Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.

{
  "article_type": "alpha_memo",
  "domain_slug": "general",
  "researka_object_type": "submission",
  "researka_submission_id": "cd219528-3723-4a61-b4ac-5e362d5a8444",
  "title": "Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy"
}